Roberge S et al. – Low–dose aspirin administrated at or before 16 weeks of gestation reduces the risk of preterm but not term preeclampsia.
A systematic review and meta–analysis of randomized controlled trials were performed.
Women who were randomized to low–dose aspirin or placebo/no treatment at or before 16 weeks of gestation were included.
The outcomes of interest were preterm preeclampsia (delivery <37 weeks) and term preeclampsia.
Pooled relative risks (RR) with their 95% confidence intervals (CI) were computed.
The search identified 7,941 citations but only five trials on a combined total of 556 women fulfilled the inclusion criteria.
When compared to controls, aspirin initiated ≤16 weeks of gestation was associated with a major reduction of the risk of preterm preeclampsia (RR 0.11, 95% CI 0.04–0.33) but had no significant effect on term preeclampsia (RR 0.98, 95% CI 0.42–2.33).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.